TOP SEMAGLUTIDE WEEK 1-12 BUNDLE SECRETS

The trial attained both of those its primary endpoints, with semaglutide two.4 mg demonstrating statistically significant and outstanding improvements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH in comparison with placebo.1Assuming th